Navigation Links
Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
Date:11/19/2007

- Study Results Determine Phase 2 Dosing Regimen -

SOUTH SAN FRANCISCO, Calif., Nov. 19 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced updated results from an ongoing Phase 1/2a open-label, dose escalation clinical trial of RAV12, its lead therapeutic antibody in development for the treatment of adenocarcinomas. The objectives of the study were to define the safety profile and maximum tolerated dose of RAV12, to define the pharmacokinetics and describe preliminary efficacy.

"The study results demonstrate that a fractionated dosing regimen allows us to deliver RAV12 with an acceptable level of toxicity, while maintaining exposure that is associated with a tumor response," said George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies. "We are particularly encouraged to have seen a clinical response in one of the patients with advanced stage gastrointestinal cancer. These findings further demonstrate the potential therapeutic value of RAV12."

Study Design

The phase 1 dose-escalation safety and pharmacokinetics (PK) trial was initiated in December 2004 in patients with recurrent adenocarcinoma who had received 1 to 3 prior treatment courses. RAV12 was administered initially four times weekly, then by fractionated dosing two or three times weekly. Thirty-three patients were treated in the dose escalation segment of the trial. Three cohorts were given a weekly dose of 0.3 mg/kg, 1.0 mg/kg, and 1.5 mg/kg, and three cohorts received fractionated dose schedules of 0.5 mg/kg twice weekly, 0.75 mg/kg twice weekly, and 0.5 mg/kg thrice weekly.

Patients all had confirmed adenocarcinoma of gastrointestinal origin or of other origin if they positively expressed the RAAG12 antigen. The majority of patients had colorectal, gastroesophageal, or pancreatic cancer. Patient responses were evaluated
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader ... cell immunotherapy to treat a variety of cancers, today ... by BVCF, a China -based healthcare ... immunotherapy company focused on the development of new therapeutics ... with Shanghai Cancer Institute and Shanghai Renji Hospital, the ...
(Date:11/26/2014)... NEW YORK and ... the leading distributor of market intelligence, MarketResearch.com is pleased ... by IQ4I Research and Consultancy focusing on the active ... about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Ingredients Global Market – Forecast to 2020 ...
(Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the ... been recognized as a winner of Red Herring,s ... Global Top 100 North America award in 2013, marking ... technology landscape. Red Herring,s Top 100 Global ... promising new companies and entrepreneurs. Red Herring editors were ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3
... SRI International, an independent nonprofit research and development organization, ... Sarnoff Corporation, its wholly owned subsidiary in Princeton, New ... welcome our new colleagues to SRI and celebrate their ... Carlson, Ph.D., president and CEO of SRI International. "Together, ...
... 3, 2011 Centre Partners Management LLC ("Centre Partners"), a ... York and Los Angeles, today announced the completion of the ... of Troy Limited (Nasdaq: HELE). Kaz is an international leader ... is valued at $260 million subject to certain closing working ...
Cached Medicine Technology:Centre Partners Announces Successful Realization of Investment in Kaz, Inc. 2Centre Partners Announces Successful Realization of Investment in Kaz, Inc. 3
(Date:11/27/2014)... Cambridge, England (PRWEB) November 27, 2014 Cambrionix ... 2014 Deloitte Technology Fast 50, a ranking of the 50 ... on percentage revenue growth over the last five years. ... addition, Cambrionix Ltd ranked first in the region of Cambridgeshire ... Kevin O’Hara, Managing Director Says:, “This award is recognition of ...
(Date:11/27/2014)... November 27, 2014 An inventor from ... embarrassing fact of life, and she wants to lessen ... minutes later, I decided that there needed to be ... said. , Easy to use and producible in design ... a woman’s private areas throughout the day. It avoids ...
(Date:11/27/2014)... Randy Dotinga HealthDay Reporter , ... seem pre-wired to acquire a second language, new research suggests. ... will likely gain a brain boost, the small study finds. ... learning," said study co-author Ping Li, co-director of the Center ... it,s even more interesting, Li said, that "the brain networks ...
(Date:11/27/2014)... -- Thanksgiving meals can pose a challenge for people ... says. Many traditional Thanksgiving dishes -- such as ... gluten-free, but "when it comes to pies, stuffing, gravy, ... Anca Safta, director of the Gluten and Allergic Digestive ... North Carolina, said in a center news release. ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Jeffrey ... years in the Charlotte area providing audits, reviews, ... services to businesses of varying size across numerous ... owners to meet all of their accounting and ... through the QuickBooks ProAdvisor Program. When asking Mr. ...
Breaking Medicine News(10 mins):Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2
... CFO and Interim CEO of Everyday Wireless to ... A Place for Mom,( http://www.aplaceformom.com/ ) announced today ... of Finance. Longstreth will oversee,the financial performance of ... strategy, as well as evaluate new business,opportunities to ...
... 24 Karen Ignagni, President,and CEO of America,s ... in response to the U.S. House of Representatives,passage ... legislation that would require Medicare,Advantage beneficiaries to pay ... impact these cuts would have on vulnerable seniors.,As ...
... 24 LCA-Vision Inc. (Nasdaq:,LCAV), a leading provider ... announces the resignation of Executive Vice President,of Finance ... J.,Celebrezze has been named interim Chief Financial Officer, ... 2007, Mr. Celebrezze has served on the,Executive Management ...
... sicker patients may be getting bare metal devices, study ... patients who got drug-coated stents did better than those ... study found. , But it isn,t a simple either-or ... the experience of almost 39,000 Medicare recipients who underwent ...
... In lab setting, they caused some machines to turn ... (HealthDay News) -- Those magic little devices that allow ... toll electronically could interfere with the operation of critical ... laboratory setting not involving actual patients, Dutch scientists found ...
... agents could have unforeseen risks in individuals with heart ... in St. Louis. The anticancer drugs which go ... with a biochemical process that promotes growth in some ... this biochemical process in mice with heart disease led ...
Cached Medicine News:Health News:A Place for Mom, Nation's Largest Assisted Living and Senior Housing Referral Service Announces New Vice President of Finance 2Health News:AHIP Statement on House Passage of H.R. 6331 2Health News:LCA-Vision Announces CFO Change 2Health News:Drug-Coated Stents Reduce Repeat Artery Procedures 2Health News:Drug-Coated Stents Reduce Repeat Artery Procedures 3Health News:Radio-Wave Devices May Play Havoc With Medical Equipment 2Health News:Radio-Wave Devices May Play Havoc With Medical Equipment 3Health News:Certain anti-cancer agents could be harmful to patients with heart disease 2Health News:Certain anti-cancer agents could be harmful to patients with heart disease 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: